Minimal Change Disease (MCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Minimal Change Disease (MCD) Market Outlook

Thelansis’s “Minimal Change Disease (MCD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Minimal change disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Minimal Change Disease (MCD) Overview

Minimal Change Disease (MCD) is a kidney disorder characterized by significant protein loss in the urine, making it one of the primary causes of Nephrotic Syndrome. Edema, notably swelling in the feet and legs that may extend to the hips and abdomen, is a prominent symptom. MCD typically presents a favorable prognosis, particularly in children, where it constitutes the most common cause of idiopathic nephrotic syndrome. Among children aged over one year with nephrotic syndrome, MCD accounts for 70% to 90% of cases, compared to only 10-15% in adults. The initial manifestation of MCD is nephrotic syndrome, marked by increased permeability of the renal membrane leading to significant protein loss, primarily albumin, due to impairment of the glomerular filtration barrier (GFB). The GFB comprises the glomerular basement membrane, the endothelium forming the inner layer, and the outer epithelial layer consisting of podocytes, specialized epithelial cells characterized by elongated foot processes, and large cell bodies running parallel to the glomerular capillary wall. Slit diaphragms, cell-to-cell connections, are located between podocyte foot processes. Steroids represent the primary treatment for MCD. Children typically achieve remission within four weeks of steroid therapy, while adults may require two months or longer. Relapse is common in both age groups. For children, prednisone therapy typically begins at 60 mg/m^2 (or 2 mg/kg) administered daily for 4-6 weeks (maximum dose: 60 mg/day), or 40 mg/m^2 (or 1.5 mg/kg) given on alternate days for a taper period of 2–5 months. A gradual reduction in dosage by 5 mg/m^2 to 10 mg/m^2 per week is recommended for at least 12 weeks, with an additional four weeks before discontinuation. Adults are usually prescribed 1 mg/kg or 2 mg/kg every other day for the initial 4–16 weeks (maximum 80 mg/day or 120 mg every other day). Dosage should be gradually tapered over six months.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: